Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by intense pruritus and eczematous lesion. In this study, topically applied substance P (SP) signifi- Taken together, these results suggest that topically administered SP may have potential as a medication for atopic dermatitis.
extrinsic allergens and itching result in a vicious cycle of the worsening of the skin lesion, causing the allergic inflammatory disease to become chronic.
Thymic stromal lymphopoietin (TSLP) plays a critical role in the initiation of the inflammatory cascade of AD at the interface between keratinocytes and dendritic cells (DCs) and also mediates itching. [5] Accordingly, elevated TSLP in atopic skin activates immature DCs to produce chemokines, such as eotaxin-2, thymus and activationregulated chemokine (TARC), and macrophage-derived chemokine (MDC), which attract Th2 cells. These Th2 cells then migrate back to the affected skin and initiate allergic inflammation by activating B cells and triggering IgE production. [6] TSLP is mainly produced by epithelial cells and pro-inflammatory cytokines, such as TNF-α and IL-1, upregulate its production. Mast cells are one of the essential sources of TSLP, as well as several pro-inflammatory cytokines including TNF-α. These cytokines are released by IgE-activated mast cells and also upregulate TSLP expression. [7] Consistently, the expression of TSLP is highly increased in the skin of patients with AD, but absent in normal skin. [7] [8] [9] [10] [11] [12] [13] SP is an endogenous neuropeptide belonging to the tachykinin family and is known to mediate intracellular signalling, mainly through G-protein coupled receptor (GPCR)-linked NK-1R, in a variety of non-neuronal as well as neuronal tissues, including the peripheral and central nervous systems. [14] [15] [16] [17] The role of SP in a variety of cell types and diseases is rather controversial. For example, at very high concentrations (10 −5 M), SP induces histamine release, which is actively implicated in neurogenic inflammation, but at low local concentrations M), SP alleviates AD progression by trophic and immune modulatory functions. [18, 19] Recently, several reports have supported the anti-inflammatory and tissue repairing roles of SP in spinal cord injury, demonstrating increases in IL-10 and in the M2 type of macrophages and decreases in TNF-α. [20] Furthermore, decreases in TNF-α and IL-17 and increased regulatory T cells (Treg) have been demonstrated in a collagen II-induced arthritis animal model. [21] SP also improves MSC's inhibitory effect on T-cell activation by stimulating tumor growth factor-β (TGF-β) secretion in long-term ex vivo expanded MSC. [22] Furthermore, SP has been newly identified as an injuryinducible messenger mobilizing MSC from the bone marrow for recruitment to the injury site. [23, 24] These newly identified physiological roles of SP led us to suggest that SP contributes to wound healing and to the regulation of chronic inflammation, rather than its classically characterized role as a pain-sensing neurotransmitter or mast cell activator.
NC/Nga mice provide a useful animal model for evaluating potential therapeutic drugs for human AD. [25] Moreover, repeated sensitization with TNCB can cause an apparent chronic dermatitis in NC/Nga mice which is similar to human AD. [26] [27] [28] In this study, using a NC/Nga AD-like dermatitis murine model induced by cutaneous sensitization with TNCB, we evaluated the effect of topical SP treatment in AD-like skin progression. We found that topical SP treatment reduces infiltration of mast cells and T cells in AD-like skin lesions, as well as reducing local inflammation in lymph nodes. These results suggest the efficacy of SP in the treatment of human diseases such as AD. These finding should be further evaluated in future clinical studies.
| MATERIALS AND METHODS

| Animals
Male 5-week-old NC/Nga mice were purchased from SLC (Shizuoka, Japan) and maintained under conventional circumstances. Animals were maintained under a 12-h light/12-h dark illumination cycle in an animal holding room and allowed to adapt to the new environment for a period of 1 week before the experiments were started.
All animals received standard chow and water ad libitum. All animal studies were performed in accordance with the Animal Experiment
Guidelines of Kyung Hee University and were approved by the Animal Use Committee at Kyung Hee University (approval number;
KHUASP[SU]-10-010).
| Induction of dermatitis
AD-like dermatitis was induced in NC/Nga mice as described by Takahashi et al [29] ( Figure 1A ). which correspond to clinically used doses. [21, 24, 30] During the drug treatment period, 0.1% TNCB was applied once a week to maintain chronic dermatitis. The mice were kept in the same environment without sensitization and were considered to be the normal (Nor) group (n = 5 for Nor).
| Evaluation of skin dermatitis severity
The severity of dermatitis in the dorsal skin was evaluated by the scoring atopic dermatitis (SCORAD) index at 0, 1, 2 and 4 weeks after drug application. [31] The clinical skin severity of dermatitis was scored as 0
(none), 1 (mild), 2 (moderate) and 3 (severe), according to the criteria of the four major clinical symptoms of AD: erythema/haemorrhage, oedema, excoriation/erosion and scaling/dryness. SCORAD was evaluated by three individuals in single-blind testing.
| Immunohistochemistry
For immunohistochemical staining, specific antibodies (Abs) to TSLP (Abcam, Cambridge, UK, 1:200) were used to stain 5-μm-thick paraffin-embedded skin samples, as described previously.
[32]
| Enzyme-linked immunosorbent assay (ELISA)
The levels of TARC in serum were measured using TARC ELISA kits (R&D Systems, Wiesbaden, Germany). All experiments were performed in triplicate with at least three independent experimental replicates.
| Analysis of lymph nodes
To evaluate immunological alterations in the entire body, axillary lymph nodes (aLNs) were collected when the mice were sacrificed at 2 weeks. Briefly, aLNs were isolated after incision of the arm skin.
Isolated tissues were measured by wet weight and normalized to body weight of each animal, and then, the specimens were fixed in 4% PFA for histological analysis.
| Statistical analysis
Results were expressed as mean ± standard deviation. Statistical analysis was performed by one-way analysis of variance (ANOVA)
followed by a Dunnett's post hoc multiple comparison test using Graph Pad Prism 5.0. (GraphPad Software, Inc. La Jolla, CA, USA). P < .05 was accepted as significant. S2 ). Compared to the AD group at 0 week, the serum IgE levels in the AD and AD-VE groups continuously escalated during the 4-week test period under the continuous low-dose treatment of TNCB to inhibit spontaneous recovery of AD symptoms. Significant differences in serum IgE levels between the test groups were shown beginning at 2 weeks rather than at 1 week as seen with the SCORAD. These differences in serum IgE levels were partially blocked by pretreatment with the CP99994. In addition, in the AD-SP group, low-dose TNCB treatment during the test period resulted in maintenance of serum IgE similar to that of the challenged one.
| RESULTS
| Topical application of SP ameliorates AD-like
In addition, ear skin was examined at 1 week of treatment in each group. Histological analysis of each ear showed significant reductions in the epidermal thickness and in infiltrating immune cells after topical treatment with SP comparing to the untreated one (Fig. S3A ).
The thickness of the epidermis in the AD controls was approximately 88 μm, which was about fivefold thicker than the normal control (18.3 ± 4.3 μm), while SP treatment (42.8 ± 8.4 μm, P < .05) reduced epidermal thickness by greater than 50%, compared to the AD controls ( Fig. S3B-C) . However, the measured thickness in the AD-VE and AD-SP-A groups was not significantly altered relative to the AD controls.
| SP treatment inhibits mast cell recruitment and degranulation in TNCB-induced AD-like lesions
As shown in In normal skin, infiltrated mast cells were barely detected and were found to be predominantly in an inactive state (indicated by an arrow head), although a few active state degranulated cells (indicated by an arrow) were observed. Highly infiltrated mast cells, regardless of their degranulation, were observed in AD skin, which was significantly prevented in AD-SP skin from 1 week (Fig. S4) . This SP-mediated prevention of mast cell infiltration was completely abolished in AD-SP-A skin and sustained up to the 2 and 4 week. Quantitative analysis of the number of infiltrated mast cells revealed approximately threefold higher levels in the AD and AD-VE groups than in normal skin (AD: 
| SP reduces chronic dermatitis in TNCB-induced NC/Nga mice
TSLP has a critical role in the initiation of the inflammatory cascade of AD, and TNF-α stimulates the release of TSLP expression. [8] Therefore, we examined TNF-α and TSLP expression by immunohistochemistry in AD-like skin samples. The expression of TNF-α and TSLP was not observed in normal mice and significantly reduced in the AD-SP group compare to the AD, AD-VE and AD-SP-A groups ( Figure 3A and Fig. S5 ). We also examined TSLP expression in primary cultured human keratinocytes to determine whether SP directly regulates its
expression. An SP-mediated reduction in TSLP expression in primary cultured keratinocytes was confirmed under inflammatory conditions induced by TNF-α (Fig. S6 ). Inflammatory stimulation with TNF-α was sufficient to induce TSLP even in cultured keratinocytes. After costimulation with SP, significant inhibition of TNF-α-induced TSLP expression was elicited. CP99994 blocked the SP-mediated reduction in TNF-α-induced TSLP expression.
Next, we measured the serum levels of TARC, one of the chemokines secreted by TSLP-activated mature DCs. TARC was markedly reduced in the serum from the AD-SP group, compared to the AD, AD-VE, and AD-SP-A groups ( Figure 3B ). Collectively, the topical application of SP in AD mice markedly reduced chronic dermatitis, along with reductions in the expression of TNF-α, TSLP and TARC.
As AD is a T-cell-mediated chronic inflammatory skin disease, the infiltration of T cells in the skin and the crosstalk between T cells and keratinocytes are important. Therefore, T-cell infiltration into the ADlike skin was also evaluated by immunohistochemistry after 2 weeks of treatment when the most significant differences in SCORAD and mast cell infiltration were observed (Fig. S7A) . (Fig. S7B) . In particular, the number of CD3 cells infiltrating to the epidermis of the AD-SP group (4.5 ± 2.5 cells/field) was significantly reduced to the levels seen in normal skin (2.3 ± 1.1 cells/field), while AD, AD-VE and AD-SP-A showed levels approximately fivefold higher than the normal group (Fig. S7C ).
| SP affects local immune responses in TNCBinduced NC/Nga mice
To determine whether topical treatment with SP affects systemic immune responses in TNCB-induced NC/Nga mice, we next examined the secondary lymphoid organs such as aLNs, adjacent to the dorsal skin lesion at the skin-draining site, the mLNs located in the peritoneal area in the mesentery and the spleen. The sizes of the isolated aLNs and cross-sections evaluated by H&E staining in the AD, AD-VE and AD-SP-A groups were much larger than those in normal mice, suggesting enhanced immune responses; the aLNs in the AD-SP group were relatively small in comparison ( Figure 4A ). These findings were also confirmed by measurements of the cross-section areas ( Figure 4B ) and total wet weight ( Figure 4C) . However, the weight of the mLNs and spleens was not significantly reduced in the AD-SP mice comparing to the AD-VE and AD-SP-A, implying that the activation of immune cells may be concentrated primarily on the local adjacent lymphoid organs (Fig. S8) .
To further evaluate the activation of the immune response in the aLNs, proliferating lymphoid cells were examined by CD3 and PCNA immunohistochemistry of the medulla and germinal centre, which are the T-cell and B-cell zones, respectively (Fig. S9A-C) . In the medullas of the AD, AD-VE and AD-SP-A groups, elevated numbers, up to 33-fold, of CD3 cells were detected; this level was significantly reduced in the SP-treated group. Moreover, PCNA-positive proliferating cells were also greatly reduced up to fivefold in the germinal centre zones of AD-SP mice. These results demonstrate that topical treatment with SP not only reduced cutaneous inflammation, but also suppressed immune responses in the adjacent lymph nodes.
Topical treatment with SP reduced IgE levels, infiltration of mast cells and secretion of TNF-α in vivo. Therefore, we carried out in vitro assays to examine the direct effects of SP in immune cells, such as RBL-2H3 cells (a rat-derived mast cell line) and U266 cells (a humanderived B-cell line). We performed mast cell migration assay using a transwell system and a β-hexosaminidase assay to examine degranulation of mast cell by SP treatment (Fig. S10) . Moreover, we examined the cytotoxicity assay and determined the amount of IgE in response to various concentration of SP (Fig. S11) . Collectively, SP did not stimulate RBL-2H3 migration and degranulation as well as U266 cell proliferation and production of IgE according to concentration of SP in vitro.
F I G U R E 3 SP treatment reduces allergic inflammation. (A)
Immunohistochemical analysis of TSLP expression in the epidermis of atopic-like skin 2 wk after drug treatment. (B) Measurement of TARC levels in the serum collected at 2 wk. The concentration of TARC was measured by ELISA (n = 5 for Nor, n = 8 for AD, AD-VE, AD-SP and AD-SP-A). The significance of differences was determined using Dunnett's post hoc multiple comparison test following ANOVA. **P < .01, ***P < .001. Scale bar = 100 μm (C) The weight of aLNs was measured after 2 wk and the relative increases from the value of normal mice are shown. Each value represents the mean ± SD. The significance of differences was determined using Dunnett's post hoc multiple comparison test following ANOVA. *P < .05, **P < .01, ***P < .001 
| DISCUSSION
In the present study, topical treatment with SP on the skin of TNCBinduced chronic dermatitis in NC/Nga mice, which is similar to human AD skin, markedly reduced the typical symptoms (Figure 1 and Fig.   S2 ). This alleviation of AD symptoms was accompanied by reduced allergic and cutaneous inflammation ( Figures 2 and 3 and Fig. S3-S5 ). As one possible mechanism for the beneficial role of SP in the alleviation of AD symptoms in TNCB-sensitized NC/Nga mice, marked reductions in TNF-α, TSLP and TARC were detected (Figure 3 and Fig. S5) and SP-mediated blockade of TNF-α-induced TSLP production was shown in cultured human keratinocytes (Fig. S6) . These immune modulatory effects of SP were also found in a secondary lymphoid organ, the aLNs adjacent to the atopic dorsal skin (Figure 4 ). In addition, the concentration of SP used for topical treatment in this study reduced the symptoms of AD, specifically the thickness of ear skin and the infiltration of immune cells (Fig. S3) . SP may be considered as a potential medication for AD-like dermatitis.
The manifestations of AD in TNCB-sensitized NC/Nga mice are caused by recurrent allergen exposure and resulting chronic inflammation of the skin. [33] The allergic response itself may be difficult to completely eradicate unless allergen exposure is completely eliminated, because memory plasma B cells are present. [34, 35] If low doses of continuous environmental allergen exposure are inevitable, clinical treatment should aim to minimize the cascade of events associated with the cutaneous allergic response. Topical treatment with SP significantly prevented this cascade by directly reducing TSLP and TNF-α expression in AD-like skin. In addition, it has been reported that topically applied SP decreases TNF-α and is accompanied by enhanced healing of full thickness open excision wounds in rats. [36] In the case of intravenous treatment with SP, an SP-induced TNF-α reduction has been consistently observed in various experimental models, including spinal cord injury and collagen II-induced rheumatoid arthritis. [20, 21] SP treatment also decreased TNF-α levels in the dermal compartment of AD skin (Fig. S5) , possibly due to reduced infiltration and degranulation of mast cells, as mast cells are the major source of TNF-α (Figure 2 and Fig. S4 ). Despite the ability of SP to induce acute mast cell activation and mediate neurogenic inflammation, several studies also have suggested that the modulation of neuropeptide activities is associated with the pathogenesis of AD. [37] [38] [39] At the concentration of SP used for AD-like dermatitis treatment in this study, SP did not affect mast cell degranulation and migration (Fig. S10) , contrary to the findings of a previous report that was evaluated at the 100-fold higher SP concentrations. [18] SP also did not activate B-cell activity (Fig. S11) . Therefore, the reduced infiltra- Recently, TSLP has been regarded as a master switch for allergic inflammation. [6] TSLP can perform its biological functions in various types of cells. TSLP activates T cells in mice as well as induces B-cell proliferation and activation in humans. [8, [40] [41] [42] Moreover, TSLP can stimulate the production of Th2 cytokines in human mast cells in combination with IL-1 and TNF-α. [8] In patients with AD, elevated TSLP production has been reported. [43] This may be caused by TNF-α-mediated chronic dermatitis and due to elevated Th2 cytokines. In this study, we clearly showed the regulation of TSLP expression by SP treatment in TNF-α-treated keratinocytes, as well as in AD-like skin in NC/Nga mice ( Fig. S5-S6 ). These effects in the down-regulation of TNF-α, mediated by reduced mast cell infiltration and TSLP expression in the epidermis, could synergistically ameliorate cutaneous inflammation in AD-like skin.
In conclusion, SP treatment alleviated typical AD symptoms in a TNCB-sensitized chronic dermatitis model in NC/Nga mice, as demonstrated by reduced allergic and cutaneous inflammation.
Therefore, we propose that SP may be a potential medication for AD.
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